A vaccine being developed by AstraZeneca and the U.K.’s Oxford University appears to be safe, early-stage clinical trials have shown, marking a promising breakthrough in the race to develop a coronavirus vaccine, although it is yet to be seen whether it protects people against the virus.Trials of the vaccine involving some 1,077 healthy adult volunteers between April and May, showed the injection triggered the creation of antibodies and white blood cells to fight coronavirus.
However, the vaccine, called AZD1222, requires larger trials to test whether it can offer protection against coronavirus. Britain has already secured a supply of 100 million doses of the vaccine, which is being developed at an unprecedented speed.The vaccine is made from a genetically engineered virus and has been modified, meaning it looks like coronavirus, but cannot trigger the infection in people. Instead, it trains the immune system to attack the virus.
He added: “However, we need more research before we can confirm the vaccine effectively protects against SARS-CoV-2 infection, and for how long any protection lasts.”Researchers working on the vaccine say they expect to begin rolling out the vaccine from October this year, months ahead of experts’ estimates that it would take until at least 2021 to find an effective injection.
That's a genetically modified virus versus another genetically modified virus 🤗
Muna farin ciki da wannan labarin.
In 1 week Moderna is also going to be testing 30K people as part of a phase 3 vaccine already. Its pretty amazing how fast things are moving to be here already. That should be huge news but the media is hardly even talking about it, 30K is a big number.
Lemme guess.....each dose will cost $10,000, with approved health insurace.
Good news
Education Education Latest News, Education Education Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: AP - 🏆 728. / 51 Read more »
Source: CNBC - 🏆 12. / 72 Read more »